183 related articles for article (PubMed ID: 34620701)
21. A noninterventional, multinational study to assess PD-L1 expression in cytological and histological lung cancer specimens.
Bubendorf L; Conde E; Cappuzzo F; Langfort R; Schildhaus HU; Votruba J; Concha-López Á; Esteban-Rodriguez I; Feng J; Devenport J; Boyiddle C; Morris S; Trunzer K; Kerr KM
Cancer Cytopathol; 2020 Dec; 128(12):928-938. PubMed ID: 32721105
[TBL] [Abstract][Full Text] [Related]
22. Programmed death-ligand 1 expression on direct Pap-stained cytology smears from non-small cell lung cancer: Comparison with cell blocks and surgical resection specimens.
Lozano MD; Abengozar-Muela M; Echeveste JI; Subtil JC; Bertó J; Gúrpide A; Calvo A; de Andrea CE
Cancer Cytopathol; 2019 Jul; 127(7):470-480. PubMed ID: 31245924
[TBL] [Abstract][Full Text] [Related]
23. Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer.
McLaughlin J; Han G; Schalper KA; Carvajal-Hausdorf D; Pelekanou V; Rehman J; Velcheti V; Herbst R; LoRusso P; Rimm DL
JAMA Oncol; 2016 Jan; 2(1):46-54. PubMed ID: 26562159
[TBL] [Abstract][Full Text] [Related]
24. An Analytical Comparison of Dako 28-8 PharmDx Assay and an E1L3N Laboratory-Developed Test in the Immunohistochemical Detection of Programmed Death-Ligand 1.
Cogswell J; Inzunza HD; Wu Q; Feder JN; Mintier G; Novotny J; Cardona DM
Mol Diagn Ther; 2017 Feb; 21(1):85-93. PubMed ID: 27667773
[TBL] [Abstract][Full Text] [Related]
25. Quantitative and qualitative characterization of Two PD-L1 clones: SP263 and E1L3N.
Smith J; Robida MD; Acosta K; Vennapusa B; Mistry A; Martin G; Yates A; Hnatyszyn HJ
Diagn Pathol; 2016 May; 11(1):44. PubMed ID: 27189072
[TBL] [Abstract][Full Text] [Related]
26. Programmed Death Ligand 1 (PD-L1) Status and Tumor-Infiltrating Lymphocytes in Hot Spots of Primary and Liver Metastases in Prostate Cancer With Neuroendocrine Differentiation.
von Hardenberg J; Hartmann S; Nitschke K; Worst TS; Ting S; Reis H; Nuhn P; Weis CA; Erben P
Clin Genitourin Cancer; 2019 Apr; 17(2):145-153.e5. PubMed ID: 30709785
[TBL] [Abstract][Full Text] [Related]
27. Agreement between Programmed Cell Death Ligand-1 Diagnostic Assays across Multiple Protein Expression Cutoffs in Non-Small Cell Lung Cancer.
Ratcliffe MJ; Sharpe A; Midha A; Barker C; Scott M; Scorer P; Al-Masri H; Rebelatto MC; Walker J
Clin Cancer Res; 2017 Jul; 23(14):3585-3591. PubMed ID: 28073845
[No Abstract] [Full Text] [Related]
28. Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma.
Rebelatto MC; Midha A; Mistry A; Sabalos C; Schechter N; Li X; Jin X; Steele KE; Robbins PB; Blake-Haskins JA; Walker J
Diagn Pathol; 2016 Oct; 11(1):95. PubMed ID: 27717372
[TBL] [Abstract][Full Text] [Related]
29. Programmed Death-Ligand 1 Immunohistochemistry Testing: A Review of Analytical Assays and Clinical Implementation in Non-Small-Cell Lung Cancer.
Büttner R; Gosney JR; Skov BG; Adam J; Motoi N; Bloom KJ; Dietel M; Longshore JW; López-Ríos F; Penault-Llorca F; Viale G; Wotherspoon AC; Kerr KM; Tsao MS
J Clin Oncol; 2017 Dec; 35(34):3867-3876. PubMed ID: 29053400
[TBL] [Abstract][Full Text] [Related]
30. Immunohistochemical comparison of three programmed death-ligand 1 (PD-L1) assays in triple-negative breast cancer.
Yoshikawa K; Ishida M; Yanai H; Tsuta K; Sekimoto M; Sugie T
PLoS One; 2021; 16(9):e0257860. PubMed ID: 34559865
[TBL] [Abstract][Full Text] [Related]
31. PD-L1 Immunohistochemistry Assay Concordance in Urothelial Carcinoma of the Bladder and Hypopharyngeal Squamous Cell Carcinoma.
Hodgson A; Slodkowska E; Jungbluth A; Liu SK; Vesprini D; Enepekides D; Higgins K; Katabi N; Xu B; Downes MR
Am J Surg Pathol; 2018 Aug; 42(8):1059-1066. PubMed ID: 29750666
[TBL] [Abstract][Full Text] [Related]
32. Clinicopathological significance of the expression of PD-L1 in non-small cell lung cancer.
Montero MA; Aricak O; Kis L; Yoshikawa A; De Petris L; Grundberg O; Pham HHN; Roden AC; Fukuoka J; Attanoos R; Guijarro R; Alarcón F; Lindström K; Ortiz-Villalón C
Ann Diagn Pathol; 2021 Apr; 51():151701. PubMed ID: 33485052
[TBL] [Abstract][Full Text] [Related]
33. Adverse prognostic value of PD-L1 expression in primary resected pulmonary squamous cell carcinomas and paired mediastinal lymph node metastases.
Keller MD; Neppl C; Irmak Y; Hall SR; Schmid RA; Langer R; Berezowska S
Mod Pathol; 2018 Jan; 31(1):101-110. PubMed ID: 28884747
[TBL] [Abstract][Full Text] [Related]
34. Comparison of assessment of programmed death-ligand 1 (PD-L1) status in triple-negative breast cancer biopsies and surgical specimens.
Noske A; Steiger K; Ballke S; Kiechle M; Oettler D; Roth W; Weichert W
J Clin Pathol; 2024 Mar; 77(4):239-245. PubMed ID: 36669878
[TBL] [Abstract][Full Text] [Related]
35. Reproducibility of PD-L1 immunohistochemistry interpretation across various types of genitourinary and head/neck carcinomas, antibody clones, and tissue types.
Wang C; Hahn E; Slodkowska E; Eskander A; Enepekides D; Higgins K; Vesprini D; Liu SK; Downes MR; Xu B
Hum Pathol; 2018 Dec; 82():131-139. PubMed ID: 30075156
[TBL] [Abstract][Full Text] [Related]
36. PD-L1 immunohistochemistry in clinical diagnostics of lung cancer: inter-pathologist variability is higher than assay variability.
Brunnström H; Johansson A; Westbom-Fremer S; Backman M; Djureinovic D; Patthey A; Isaksson-Mettävainio M; Gulyas M; Micke P
Mod Pathol; 2017 Oct; 30(10):1411-1421. PubMed ID: 28664936
[TBL] [Abstract][Full Text] [Related]
37. Consistency of tumor and immune cell programmed cell death ligand-1 expression within and between tumor blocks using the VENTANA SP263 assay.
Scorer P; Scott M; Lawson N; Ratcliffe MJ; Barker C; Rebelatto MC; Walker J
Diagn Pathol; 2018 Jul; 13(1):47. PubMed ID: 30041679
[TBL] [Abstract][Full Text] [Related]
38. Comparative analysis of programmed cell death ligand 1 assays in renal cell carcinoma.
Lee KS; Choe G; Yun S; Lee K; Moon S; Lee S; Hong SK; Byun SS; Lee SE
Histopathology; 2020 Jul; 77(1):67-78. PubMed ID: 31872892
[TBL] [Abstract][Full Text] [Related]
39. Implementation of PD-L1 22C3 IHC pharmDxTM in Cell Block Preparations of Lung Cancer: Concordance with Surgical Resections and Technical Validation of CytoLyt® Prefixation.
Lou SK; Ko HM; Kinoshita T; MacDonald S; Weiss J; Czarnecka-Kujawa K; Boerner SL; Yasufuku K; Tsao MS; Schwock J
Acta Cytol; 2020; 64(6):577-587. PubMed ID: 32599583
[TBL] [Abstract][Full Text] [Related]
40. Validation of E1L3N antibody for PD-L1 detection and prediction of pembrolizumab response in non-small-cell lung cancer.
Song L; Zeng L; Yan H; Xu Q; Xia Q; Lei J; Chen X; Hu X; Wang Z; Liu H; Yang N; Zhang Y
Commun Med (Lond); 2022 Nov; 2(1):137. PubMed ID: 36352254
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]